News

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, discontinuation rates were low across all groups.

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Findings from the ECHELON-3 trial supported the approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

Serial CTRS, an AI-powered tool, has been granted FDA breakthrough device designation for classifying patients with NSCLC.

Envafolimab plus suvemcitug and FOLFIRI showed early efficacy and manageable safety in MSS/pMMR colorectal cancer, according to phase 2 trial data.

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.

Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine showed no recurrence at data cutoff.

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

More excellent responses occurred for patients with low-risk thyroid cancer who had thyroidectomies without radioiodine vs treatment with radioiodine.

Thermal ablation was associated with no treatment-related deaths and fewer AEs compared to surgical resection in patients with CRC liver metastases.

Adolescent and young adult survivors of cancer face increased substance use risks due to developmental delays, limited support, and coping mechanisms, necessitating targeted prevention.

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

In BRAF V600E-mutant metastatic colorectal cancer, encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS compared with chemotherapy.

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Zipalertinib demonstrated efficacy in pretreated NSCLC with EGFR exon 20 insertion mutations, meeting the primary endpoint of ORR in the REZILIENT1 study.

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.

Inavolisib in combination with palbociclib and fulvestrant improved overall survival compared to palbociclib and fulvestrant alone in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to data from the LIGHT trial.

Sintilimab with neoadjuvant chemoradiotherapy enhanced pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.